A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1Since this is a Phase I/IIa trial and the primary outcomes are focused on measuring side effects, dose-limiting toxicities, and safety signals rather than whether the drug shrinks tumors, what does that mean for what we'd realistically hope to learn from my participation?
2. 2AZD8205 can be given alone or in combination with another agent in this trial — which approach would apply to me given my specific cancer type and situation, and how does the combination affect the safety profile compared to AZD8205 alone?
3. 3The trial is actively monitoring serious adverse events, ECG changes, and lab abnormalities — are there any known or early signals from this drug's mechanism that I should be aware of before deciding whether to discuss enrolling?
4. 4How does my specific cancer diagnosis — whether it's breast, ovarian, endometrial, biliary tract, or squamous non-small cell lung cancer — affect how well I might fit the eligibility criteria for this study, and are there any prior treatment requirements I'd need to meet?
5. 5Given that this is an early-phase trial still establishing safe dosing, would my doctor recommend considering standard treatment options first, or is there a reason this trial might make sense to explore at this point in my care?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.